Share this video  

NCRI 2021 | Future developments in CRC

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, shares the latest developments in the field of colorectal cancer, including an increased focus on immunotherapy, as well as targeting BRAF and HER2. Dr Seligmann additionally focuses on the randomized phase III FOxTROT trial (NCT00647530), which assesses neoadjuvant chemotherapy in patients with colorectal cancer fit for surgery, and the Phase II NICHE trial (NCT03026140), which investigated neoadjuvant immunotherapy in early stage colorectal cancer. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.


Dr Seligmann has received honoraria/travel/consultancy fees from Servier, Merck Serono, Pierre Fabre, Roche Diagnostics, BMS, and GI Connect.